Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Cardlytics, Lowers Price Target to $8

Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $14 to $8.

CEL-SCI Q3 EPS $(0.23) Up From $(0.25) YoY

By Benzinga Newsdesk

Today, 7:37 AM

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.23) per share. This is a 8 percent increase over losses of $(0.25) per share from the same period last year.

CVM

Why Miromatrix Medical Shares Are Falling 40%

By Henry Khederian

Today, 7:37 AM

Miromatrix Medical Inc (NASDAQ: MIRO) shares are trading lower by 42.41% to $1.42 after the company announced pricing of a $10 million public offering of common stock.

MIRO

FDA
News

CytRx Comments On Orphazyme Complete Response Letter From FDA

By Benzinga Newsdesk

Today, 7:37 AM

CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S

CYTR